Page 2


  • Two people in white coats work at a laboratory bench.
    Image attribution tooltip
    Adene Sanchez via Getty Images
    Image attribution tooltip

    Private biotech funding rises as venture firms deploy cash

    Twenty-six drugmakers closed fundraising rounds worth more than $100 million in the first quarter, according to HSBC data shared with BioPharma Blog.

  • An injection pen containing the drug semaglutide lies on a white plate.
    Image attribution tooltip
    Douglas Cliff via Getty Images
    Image attribution tooltip
    Obesity drugs

    Trial shows Wegovy can ease heart failure symptoms

    The results were the second time Novo has shown its weight loss treatment can help with the condition, and may help it secure broader use of the drug.

  • Business Woman pushing large stone uphill
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Women want to participate in clinical trials. Lack of flexibility is still a problem.

    Underrepresentation of women in clinical trials affects the resulting drugs that become available later. Even small changes could boost participation.

  • An illustration of T cells attacking a cancer cell
    Image attribution tooltip
    Peddalanka Ramesh Babu via Getty Images
    Image attribution tooltip

    FDA approves CAR-T therapies from J&J, Bristol Myers for earlier myeloma use

    The FDA quickly followed last week’s clearance of Bristol Myers’ Abecma with an OK for J&J’s Carvykti, but gave the rival treatments different labels.

    Updated April 8, 2024
  • A stock photo of blocks arranged to illustrate layoffs
    Image attribution tooltip
    Andrii Yalanskyi via Getty Images
    Image attribution tooltip

    Boehringer Ingelheim to lay off staff amid biosimilar challenges

    The German pharmaceutical company is “streamlining” its custom-facing teams behind Cyltezo, a copycat version of AbbVie’s immune disease drug Humira.

  • The logo of Amylyx Pharmaceuticals is seen through an office window.
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip

    Amylyx to pull ALS drug from market in rare move

    In the wake of a major trial failure, the company is withdrawing Relyvrio and cutting costs with a restructuring that involves laying off 70% of its employees.

  • The Nasdaq MarketSite is seen on October 12, 2022 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip
    Emerging biotech

    Contineum prices biotech’s latest IPO, raising $110M for neuroinflammatory drugs

    The offering keeps new biotech stock offerings on their strongest pace in three years, accompanying an uptick in private company funding.

  • Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J to acquire Shockwave Medical for $13.1B

    The deal comes just over a week after The Wall Street Journal reported the companies were discussing a merger.

    Updated April 5, 2024
  • The Merck & Co. sign at the company's building in Summit, New Jersey.
    Image attribution tooltip
    Kena Betancur via Getty Images
    Image attribution tooltip

    Merck puts KRAS cancer drug competitor to the test

    A Phase 3 study will compare Merck’s experimental KRAS inhibitor together with its immunotherapy Keytruda against Keytruda alone in lung cancer.

  • An illustration of antibiotic-resistant bacteria, including Staphylococcus aureus
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip

    FDA approves new antibiotic for several hard-to-treat infections

    Swiss pharma Basilea has won clearance for Zevtera after a long development journey, but is still searching for a commercial partner in the U.S.

    FDA
  • A 3D visualization of antibody drug conjugates.
    Image attribution tooltip
    Love Employee via Getty Images
    Image attribution tooltip

    Genmab buys ProfoundBio for $1.8B, adding to ADC dealmaking flurry

    The buyout continues a surge in M&A for developers of antibody-drug conjugates and gives Genmab a potential competitor to a medicine AbbVie recently purchased in a multibillion-dollar acquisition.

  • A 3D visualization of red blood cells traveling through a blood vessel.
    Image attribution tooltip
    Kahan Shan via Getty Images
    Image attribution tooltip
    Emerging biotech

    Diagonal starts up with $128M to make better ‘activator’ antibody drugs

    The startup claims to have a more efficient way to develop biologic drugs that treat disease by turning on cellular pathways, rather than blocking them.

  • A street sign for Wall Street in front of the facade of the New York Stock Exchange.
    Image attribution tooltip
    JaysonPhotography via Getty Images
    Image attribution tooltip

    Paragon’s hub-and-spoke biotech model yields another reverse merger

    Oruka Therapeutics is the third startup from Paragon to go public since last year, and the second to do so by combining with another biotech.

  • A photo of Sekar Kathiresan, CEO of Verve Therapeutics
    Image attribution tooltip
    Seth Babin/BioPharma Blog
    Image attribution tooltip

    Verve pauses base editing trial, shifts strategy after treatment side effect

    Lab abnormalities in one study participant led the company to halt enrollment and prioritize a different version of its genetic medicine for heart disease.

  • Brain investment
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    A dementia-focused VC digs past amyloid for new kinds of brain drugs

    The Dementia Discovery Fund set out to spark research into new approaches for diseases like Alzheimer’s, even as anti-amyloid therapies reach patients.

  • A stylized stock chart is superimposed over a picture of U.S. dollars.
    Image attribution tooltip
    Maximusnd via Getty Images
    Image attribution tooltip

    Roivant reveals positive immune drug data, share buyback plans

    A Pfizer drug licensed to a Roivant subsidiary surpassed expectations in a type of uveitis, while a stock purchase plan will see Roivant buy out shares owned by Sumitomo Pharma.

  • An illustration of immune cells attacking a tumor.
    Image attribution tooltip
    Meletios Verras via Getty Images
    Image attribution tooltip

    Gritstone shares fall on shaky study results for colorectal cancer vaccine

    While the company claimed its shot showed signs of working in a Phase 2 trial, the data weren’t strong enough to prove a treatment benefit.

  • People walk past the Nasdaq MarketSite on October 12, 2022 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    Acorda files for bankruptcy, reveals asset sale plan

    Stalking horse bidder Merz Therapeutics could get rights to Acorda’s three marketed drugs if its $185 million proposal holds.

  • An illustration of immune system T cells attacking cancer cells.
    Image attribution tooltip
    Meletios Verras via Getty Images
    Image attribution tooltip

    Ginkgo, in search of more cell therapy tools, buys another startup

    A deal for Modulus Therapeutics is the latest move by Ginkgo to accumulate technologies that can help other companies develop cellular medicines.

  • Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    AstraZeneca gets FDA OK for rare disease drug acquired in Alexion buyout

    The approval of Voydeya as an add-on therapy for an uncommon blood disease validates a bet Alexion made on original developer Achillion five years ago.

    FDA
  • A photo of Vertex Pharmaceuticals' Boston headquarters.
    Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals
    Image attribution tooltip

    Vertex moves kidney disease drug into late-stage testing

    The drug, inaxaplin, is an important pipeline prospect for Vertex, which is working to expand beyond the cystic fibrosis medicines that made its name.

  • Claudia Ulbrich, CEO, Cardior Pharmaceuticals
    Image attribution tooltip
    Permission granted by Cardior
    Image attribution tooltip

    ‘The heart is back,’ says Cardior CEO, as Novo’s $1B deal boosts field

    Novo Nordisk’s acquisition of Cardior Pharmaceuticals is a bet on new approaches to cardiovascular disease, says Cardior head Claudia Ulbrich.

  • Image attribution tooltip
    National Cancer Institute, NIH
    Image attribution tooltip

    Bristol Myers says KRAS drug succeeds in key trial

    Confirmatory results for Krazati, which Bristol Myers acquired via its buyout of Mirati, could help the drug win full approval while Amgen has been set back.

  • A person in hiking gear stands for a photograph with mountains in the background.
    Image attribution tooltip
    Permission granted by Art Krieg
    Image attribution tooltip
    Emerging biotech

    Biotech veteran Art Krieg postpones retirement to build an unorthodox drug startup

    With Zola Therapeutics, Krieg plans to design and sell a series of cancer immunotherapies without the help of outside investors, he told BioPharma Blog.

  • An illustration of a stock market graph and bar chart price display.
    Image attribution tooltip
    maciek905 via Getty Images
    Image attribution tooltip
    Emerging biotech

    Boundless Bio breaks IPO lull with $100M fundraise

    The startup’s performance will test investors’ appetite for early-stage drugmakers, as Boundless has only advanced as far as Phase 1 clinical trials.